Effects of cilostazol on cerebral blood flow, P300, and serum lipid levels in the chronic stage of cerebral infarction

Mochizuki, Yoko; Oishi, Minoru; Mizutani, Tetsuya

doi:10.1053/jscd.2001.24657

Cited by 21 publications

(18 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A previous study has shown that cilostazol is effective in improving CBF and P300 latency in patients with chronic‐stage cerebral infarction 25 . The current results show that another possible mechanism is the direct action of cilostazol on AD pathology.…”

Section: Discussionsupporting

confidence: 59%

“…Furthermore, some investigators have suggested an underlying mechanism by which cilostazol protects against cognitive decline 25–29 . A possible mechanism for this is increased CBF and the subsequent prevention of demyelination or microinfarction of the cerebral white matter, not as yet depicted by neuroimaging studies, which might be associated with the progression of AD 26,30 …”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: A pilot study

Sakurai

Hanyu

Sato

et al. 2012

Geriatrics Gerontology Int

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 59%

Section: Discussionmentioning

confidence: 99%

Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: A pilot study

Sakurai

Hanyu

Sato

et al. 2012

Geriatrics Gerontology Int

View full text Add to dashboard Cite

show abstract

“…In line with such an effect is the demonstration of improvement in cerebrovascular blood flow in patients with stroke (Kobayashi et al, 1985;Mochizuki et al, 2001). However, the mechanisms regarding its beneficial effect remain unclear.…”

Section: Introductionmentioning

confidence: 95%

Alterations in Nitric Oxide and Endothelin-1 Bioactivity Underlie Cerebrovascular Dysfunction in ApoE-Deficient Mice

Yamashiro

Milsom

Duchêne

et al. 2010

J Cereb Blood Flow Metab

View full text Add to dashboard Cite

Hypercholesterolemia is associated with decreased nitric oxide (NO) bioavailability and endothelial dysfunction, a phenomenon thought to have a major role in the altered cerebral blood flow evident in stroke. Therefore, strategies that increase endothelial NO production have potential utility. Vascular reactivity of the middle cerebral artery (MCA) from C57BL/6J wild-type (WT) mice, apolipoprotein-E knockout (ApoE À/À ) mice, and mice treated with the phosphodiesterase inhibitor cilostazol (100 mg/kg) was analyzed using the tension myograph. Contractile responses to endothelin-1 were significantly enhanced in MCA from ApoE À/À mice compared with WT mice (P < 0.01), an effect absent in cilostazol-treated ApoE À/À mice. Acetylcholine-induced relaxation (which is entirely NO-dependent) was significantly impaired in MCA of ApoE À/À mice compared with WT mice (P < 0.05), again an effect prevented by cilostazol treatment. Endothelial NOS phosphorylation at Ser 1179 was decreased in the aorta of ApoE À/À mice compared with WT mice (P < 0.05), an effect normalized by cilostazol. Taken together, our data suggest that the endothelial dysfunction observed in MCA associated with hypercholesterolemia is prevented by cilostazol, an effect likely due to the increase in eNOS phosphorylation and, therefore, activity.

show abstract

“…It also reduced cell death due to apoptosis and oxidative stress, with activity in proinflammatory cytokines, DNA fragmentation, 51 besides reducing size of ischemic lesions in experimental studies. 48 In clinical research, cilostazol proved to be effective in increasing cerebral blood flow, [64][65][66] in reducing relative risk of recurrent cerebral infarction, especially lacunar, and was useful in secondary prevention. 61 …”

Section: Resultsmentioning

confidence: 99%

“…63 Prevention of silent cerebral infarction was reported in a study of 89 patients, placebo-controlled, and with a 3.6-year follow-up (p < 0.001). Mochizuki et al, using single photon emission computed tomography (SPECT), 64 demonstrated increased cerebral blood flow in a non-controlled study with a 3-month follow-up. Oishi et al reported increased blood flow in the frontal white matter, temporal and occipital cortex in relation to ticlopidine in patients in chronic stage of cerebral infarction, also using SPECT.…”

Section: Actions Of Cilostazol In Central Nervous System Blood Flowmentioning

confidence: 99%

Contribuição na prevenção da isquemia cerebral pelo cilostazol, um inibidor da fosfodiesterase III: revisão de literatura

2008

View full text Add to dashboard Cite

This literature review aims at presenting the main possibilities for the clinical application of cilostazol in the central nervous system. Cilostazol, a selective phosphodiesterase type III inhibitor, increases adenosine 3',5'-cyclic monophosphate levels on platelets, endothelial and smooth muscle cells, having vasodilatory, antiplatelet and antithrombotic properties. Currently, it is the first-choice drug for intermittent claudication, due to peripheral occlusive vascular disease. In addition, there is evidence showing that cilostazol is efficacious in cerebral atherosclerotic process, resulting in increase of blood flow and volume and preventing infarctions, especially lacunar and recurrent, since it reduces cellular death due to apoptosis and oxidative stress in white and gray substances.Keywords: Phosphodiesterase inhibitors, cerebral infarction, cerebral blood flow, cilostazol. RESUMOEsta revis•o bibliogr‚fica objetiva expor estas pesquisas sobre as a€ƒes do cilostazol no sistema nervoso central. O cilostazol " uma droga que demonstrou exercer inibi€•o seletiva e potente da fosfodiesterase tipo III, ocasionando o aumento de adenosina c…clica -3',5'-monofosfato nas plaquetas, nas c"lulas endoteliais e nas c"lulas musculares lisas, sendo classificado como vasodilatador, antiagregante plaquet‚rio e antitromb ‡tico. ˆ o f‚rmaco de primeira escolha na claudica€•o intermitente devido ‰ doen€a arterial obstrutiva perif"rica. Al"m disso, h‚ evidŠncias de que o cilostazol " eficaz no processo ateroscler ‡tico cerebral, promovendo aumento do fluxo e volume sang‹…neos e prevenindo infartos, especialmente lacunares e recorrentes, por diminuir a morte celular devido ‰ apoptose e ao estresse oxidativo nas substOEncias branca e parda.Palavras-chave: Inibidores de fosfodiesterase, infarto cerebral, fluxo sang‹…neo cerebral, cilostazol.

show abstract

Effects of cilostazol on cerebral blood flow, P300, and serum lipid levels in the chronic stage of cerebral infarction

Cited by 21 publications

References 18 publications

Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: A pilot study

Effects of cilostazol on cognition and regional cerebral blood flow in patients with Alzheimer's disease and cerebrovascular disease: A pilot study

Alterations in Nitric Oxide and Endothelin-1 Bioactivity Underlie Cerebrovascular Dysfunction in ApoE-Deficient Mice

Contribuição na prevenção da isquemia cerebral pelo cilostazol, um inibidor da fosfodiesterase III: revisão de literatura

Contact Info

Product

Resources

About